Safety and activity findings from a phase 1b escalation study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with carboplatin in patients with platinum-sensitive ovarian cancer
Author:
Publisher
Elsevier BV
Subject
Obstetrics and Gynecology,Oncology
Reference43 articles.
1. Optimal first-line treatment in ovarian cancer;Raja;Ann. Oncol.,2012
2. Weekly vs. every-3-week paclitaxel and carboplatin for ovarian Cancer;Chan;N. Engl. J. Med.,2016
3. A comparison of the toxicity and tolerability of two intraperitoneal chemotherapy regimens for advanced-stage epithelial ovarian cancer;Bouchard-Fortier;Gynecol. Oncol.,2016
4. Treatment options in recurrent ovarian cancer: latest evidence and clinical potential;Luvero;Ther. Adv. Med. Oncol.,2014
5. Ovarian cancer standard of care: are there real alternatives?;Della Pepa;Chin. J. Cancer,2015
Cited by 45 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Efficacy and safety of mirvetuximab soravtansine in recurrent ovarian cancer with FRa positive expression: A systematic review and meta-analysis;Critical Reviews in Oncology/Hematology;2024-02
2. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors;Journal of Hematology & Oncology;2024-01-04
3. The evolving landscape of antibody-drug conjugates in ovarian cancer: new drugs for a new era;Current Opinion in Obstetrics & Gynecology;2024-01-03
4. Antibody–Drug Conjugates for the Treatment of Gynecologic Cancer;Advances in Oncology;2024-01
5. Mirvetuximab soravtansine-gynx: first antibody/antigen-drug conjugate (ADC) in advanced or recurrent ovarian cancer;International Journal of Gynecologic Cancer;2023-12-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3